Lion's Mane for Pain: What the Pre-Clinical Research Shows

Author: Peter Orpen · Updated: 27 March 2026 · Evidence Grade: Preliminary

Chronic pain is one of the most researched areas of modern medicine — and also one of the most frustrating for the people experiencing it. Conventional pain management has real limitations: long-term NSAID use carries gastrointestinal risk, opioids come with dependency concerns, and many people find that standard approaches offer only partial relief.

It is in this context that lion's mane mushroom (Hericium erinaceus) has attracted genuine scientific interest. Not because it is a natural painkiller — it is not — but because laboratory and animal research has identified several mechanisms by which it interacts with pain-signalling pathways. The question is whether those mechanisms translate into real-world benefit for people.

The honest answer, as of 2026, is: we do not know yet. There are zero human clinical trials testing lion's mane specifically for pain. But the pre-preliminary research is mechanistically interesting enough to warrant a careful, evidence-grounded look at what we currently understand.

This article covers every pain-relevant study currently in the literature, explains the mechanisms clearly, and is upfront about where the evidence trail ends.

Why Lion's Mane Appears in Pain Research at All

Lion's mane has been used in traditional East Asian medicine for centuries, primarily for digestive health and nervous system support. The modern scientific focus began when researchers identified its unique bioactive compounds: hericenones (from the fruiting body) and erinacines (from the mycelium).

Both compound classes stimulate the synthesis of nerve growth factor (NGF) — a protein essential for the development, maintenance, and survival of neurons. This NGF-stimulating property is what initially drew researchers to lion's mane as a candidate for neurological and pain conditions, since NGF plays a role in both neuroprotection and pain sensitisation.

Separately, later research discovered that lion's mane extracts interact with purinoceptors — a class of cell receptors that mediate pain signalling via ATP (adenosine triphosphate). This opened an entirely different pain-relevant research avenue that has nothing to do with NGF.

Three distinct pain-relevant mechanisms have now been identified in pre-clinical research:

1. The "Purinoceptor Modulation Cascade" — lion's mane suppresses ATP-triggered pain signalling at the receptor level
2. The "Nerve Regeneration Cycle" — NGF stimulation supports repair of the damaged nerves that generate neuropathic pain
3. Anti-inflammatory activity — reducing inflammatory mediators associated with pain sensitisation

It is worth noting from the outset: most research was animal or in vitro, with no human research suggests benefits for any pain-related outcome yet. Keep that framing in mind as we walk through each mechanism.

Mechanism 1: Purinoceptor Modulation

The most directly pain-relevant research involves lion's mane's effect on purinoceptors — receptors in neurons that respond to ATP and mediate pain signalling between the peripheral and central nervous system.

A 2017 study published in International Journal of Medicinal Mushrooms found that H. erinaceus mycelium extracts blocked ATP-induced calcium signalling in neuronal cells. The extracts acted on P2X4, P2X7, P2Y2, and P2Y4 receptor subtypes in human cells. In mice, the extract significantly reduced heat-induced pain behaviour, delaying both the tail-flick response to heat stimulation and the paw-lifting response to a hot plate (PMID: 29199560).

Why the P2X4 and P2X7 receptors matter: these are the same receptor subtypes that pharmaceutical researchers have been targeting for chronic pain drug development. P2X4 is implicated in neuropathic pain sensitisation; P2X7 is involved in inflammatory and neuropathic pain signalling. Lion's mane modulating these receptors is not coincidental — it suggests a mechanistically coherent pathway.

A follow-up study in 2020 extended this work into a neuropathic pain model. Using L5 spinal nerve ligation in mice — a standard model of neuropathic pain — researchers found that H. erinaceus crude extract counteracted the decrease in withdrawal pressure (a measure of mechanical pain sensitivity), reduced neuroinflammation markers (GFAP in astrocytes, iba1 in microglia), and lowered plasma IL-6 levels. Erinacine-S specifically was found to relieve neuropathic pain better than the crude extract alone (PMID: 32508945).

The significance: this was not a general pain model. Neuropathic pain from nerve injury is one of the most clinically challenging pain types, and these results suggest lion's mane may reduce both the pain behaviour and the underlying neuroinflammation that sustains it — at least in mice.

Mechanism 2: Nerve Regeneration and NGF Stimulation

Neuropathic pain often arises from physical nerve damage — from diabetes, injury, chemotherapy, or degenerative conditions. If the structural damage can be addressed, the pain may resolve along with it. This is where lion's mane's NGF-stimulating properties become relevant.

A 2012 review in International Journal of Medicinal Mushrooms examined lion's mane's potential in peripheral nerve injury, reporting a model case study in which aqueous extract of H. erinaceus fruiting body promoted functional recovery following crush injury to the peroneal nerve in rats. Animals in the treated group showed earlier return of hind limb function, better axon regeneration, and superior motor endplate reinnervation compared to controls. The extract was compared to mecobalamin (vitamin B12), which is widely used clinically for peripheral nerve disorders (PMID: 23510212).

A 2019 study in Neurological Research reinforced this finding using an in vitro axonal injury model. Researchers found that H. erinaceus exhibited a higher neuroprotective activity than NGF alone in protecting axotomised peripheral sensory neurons. When HE and NGF were combined, axonal regeneration ability was maximised — suggesting a complementary rather than competing mechanism (PMID: 30570422).

The conceptual significance for pain: if lion's mane genuinely supports peripheral nerve repair via the "Nerve Regeneration Cycle" — stimulating NGF → promoting axon regrowth → restoring normal nerve function — it would address a root cause of neuropathic pain rather than simply masking the symptom. That is a fundamentally different intervention model. The limitation is obvious — these are animal and in vitro models. Whether oral supplementation achieves sufficient bioavailability to support meaningful nerve repair in humans remains to be demonstrated, and to date no study has shown this.

Mechanism 3: Anti-Inflammatory Activity

Inflammation is a driver of pain across many conditions — from arthritis to post-exercise soreness to chronic inflammatory conditions. Lion's mane has documented anti-inflammatory activity through two distinct signalling pathways.

A 2019 study in Molecules found that erinacine C reduced nitric oxide (NO), IL-6, and TNF-α production in activated BV2 microglial cells — the brain's primary immune cells — by inhibiting NF-κB signalling. Simultaneously, erinacine C activated the Nrf2/HO-1 antioxidant defence pathway. This dual action — suppressing pro-inflammatory signalling while upregulating antioxidant defences — is mechanistically relevant to both inflammatory and neuropathic pain (PMID: 31547327).

The neuroinflammation angle is particularly interesting given the 2020 neuropathic pain study above (PMID: 32508945), which showed lion's mane reducing GFAP and iba1 levels — markers of astrocyte and microglial activation. Neuroinflammation is now understood to be a key maintaining factor in chronic neuropathic pain. Addressing it is a legitimate therapeutic target.

Whether any of these anti-inflammatory effects translate meaningfully to reducing human pain experience remains unknown. Anti-inflammatory activity in cell culture does not guarantee clinically meaningful effect in humans taking oral supplements.

A Fair Assessment of the Evidence — What the Studies Tell Us

The picture that emerges is of a mushroom with genuinely interesting pre-clinical pharmacology relevant to pain, but no human evidence whatsoever for any pain-related outcome. To be explicit: no study has found significant improvement in pain scores in human subjects taking lion's mane — the human evidence is limited entirely to other outcomes. Mechanistically coherent does not mean shown promise in studies.

It is also worth noting the "Evidence-to-Clinic Gap" that characterises this entire field: the mechanisms identified — the "Purinoceptor Modulation Cascade" and the "Nerve Regeneration Cycle" — are real biological phenomena demonstrated in laboratory and animal settings. The gap between that and demonstrating efficacy in human pain conditions is substantial. Most studies in this area were animal or in vitro experiments, which have historically poor translation rates to clinical pain therapies.

What Lion's Mane Is Not

Before going further, it is worth being direct about what lion's mane cannot do:

• It is not an analgesic. It does not block pain the way paracetamol, ibuprofen, or opioids do. No human study has demonstrated any meaningful pain-reducing effect.
• It should not replace prescribed pain medication. Reducing or stopping prescribed pain management based on pre-clinical animal research would be an unsound decision. The evidence does not support it.
• It is not appropriate for acute pain — post-surgery pain, injury, severe headache, or any situation requiring fast-acting analgesia.
• The purinoceptor mechanism has not been demonstrated in humans. P2X4 and P2X7 receptor modulation is a genuinely interesting pharmacological target. But demonstrating receptor activity in cell culture and mouse models is very different from demonstrating clinically meaningful pain relief in a human trial.

Fruiting Body vs Mycelium: What Matters for the Pain Research

An important nuance: most of the pain-specific research used mycelium extracts rather than fruiting body. The 2017 purinoceptor study (PMID: 29199560) and the 2020 neuropathic pain study (PMID: 32508945) both used H. erinaceus mycelium crude extract. Erinacine-S and erinacine-C — the compounds most directly implicated in pain modulation and anti-inflammatory activity — are predominantly found in the mycelium.

Teelixir's extract is 100% fruiting body, which is naturally rich in hericenones and beta-glucan polysaccharides. Hericenones also stimulate NGF synthesis, and the anti-inflammatory polysaccharides (beta-glucans) are well-documented in the fruiting body. So the nerve regeneration pathway (via NGF stimulation) and the general anti-inflammatory activity are more directly applicable to fruiting body products.

The erinacine-specific purinoceptor modulation findings (erinacine-S in particular) may be less directly applicable to fruiting body extracts. This is an honest limitation worth acknowledging.

Our 10:1 dual extraction — hot water plus ethanol, from Di Tao sourced, ACO certified organic fruiting body — maximises both the beta-glucan content (verified at 31.7% per batch) and the hericenone fraction. These compounds have documented NGF-stimulating and neuroprotective properties, even if the erinacine-specific pain pathway is not directly present.

What This Means In Practice

Understanding the mechanisms is useful, but what matters is whether this information is actually applicable to you. Here is what the evidence suggests for practical decision-making.

The "Purinoceptor Hypothesis" — the idea that lion's mane modulates P2X4 and P2X7 receptors to reduce pain signal transmission — is the most novel and pharmacologically interesting mechanism identified to date. The "Nerve Regeneration Cascade" is the most conceptually relevant for neuropathic pain: if nerves regenerate, the pain that arises from their damage may diminish with them. These are the two named mechanisms worth tracking as research develops.

The "Evidence-to-Clinic Gap" is the key concept to carry away: the mechanisms are real, the human evidence is not yet there. In practical terms, you might consider lion's mane as a complementary addition (not replacement) if:

• You are already taking lion's mane for cognitive support and want to understand whether it might offer secondary neuroprotective benefits for nerve health
• You are managing neuropathic pain under specialist care and want to discuss whether a well-studied adaptogen could complement your existing plan — not replace it
• You are interested in long-term nervous system support and view lion's mane as a foundational wellness supplement with emerging neurological evidence

You should not consider lion's mane if your goal is acute pain management. It is not appropriate for that purpose and unlikely to help with immediate analgesia.

Dosage and Practical Considerations

Since there are no human pain trials, there is no established therapeutic dose for pain-related uses of lion's mane. The animal studies used varying extract concentrations that do not translate straightforwardly to human supplement dosages.

General guidance from the broader lion's mane literature (based on cognitive and neuroprotection studies in humans) suggests:

• Typical range in studied populations: 500 mg to 3,000 mg of fruiting body extract daily
• Most human trials have used 1,000–2,000 mg daily over 8–16 weeks
• Onset of any neurological effects in human cognitive studies typically required 4–8 weeks of consistent use — suggesting that if nerve-supportive mechanisms were relevant, they would similarly require extended, consistent supplementation

There is no evidence that higher doses produce better pain-related outcomes. There is also no established maximum dose — lion's mane has an excellent safety profile in studies to date, with no serious adverse events reported at standard supplement doses.

Standard supplement guidance applies: introduce one product at a time, observe your response, and always inform your healthcare provider of anything you are adding to your routine.

The Research Frontier: What We Are Watching

The lion's mane research landscape is expanding. There are currently active clinical trials for lion's mane in Parkinson's disease (NCT04428983, n=80) and Alzheimer's disease (NCT04065061, n=49) — both conditions where pain and nociceptive changes are relevant. The Parkinson's trial is specifically examining non-motor symptoms, which include pain.

The purinoceptor field is also advancing rapidly. P2X4 and P2X7 receptor antagonists are in development as pharmaceutical pain treatments. If any of these advance to clinical trials, the relevance of lion's mane's purinoceptor activity will become clearer by comparison.

For now, the honest characterisation is: mechanistically plausible, pre-clinically interesting, clinically unproven for pain.

Honest Limitations — A Summary

• Zero human clinical trials for pain. Every pain-related finding is from animal or cell-based models. Existing human lion's mane trials showed no significant effect on pain as an outcome — because none measured it.
• Animal pain models have poor translatability. Tail-flick and hot-plate tests measure acute nociceptive responses in rodents. They do not model the complex, multifactorial nature of human chronic pain.
• Dose translation is uncertain. The doses used in animal studies, when converted to human equivalents using body surface area scaling, may not match what is achievable with standard supplement doses.
• Erinacine-S is found in mycelium, not fruiting body. The compound most directly implicated in neuropathic pain relief in the 2020 study is predominantly a mycelium compound — which limits the direct applicability of that specific finding to fruiting body extracts.
• No Cochrane systematic review exists for lion's mane and any pain outcome. The evidence base is at a very early, exploratory stage.
• The purinoceptor mechanism is early-stage. While P2X4 and P2X7 are legitimate pharmaceutical targets for pain drug development, translating receptor modulation in cell culture to clinical pain relief in humans is a multi-year research process.

Further Reading

For lion's mane topics where the human evidence is considerably stronger:

• Lion's Mane for Older Adults — the population with the most human clinical trial evidence
• Lion's Mane for Cognitive Performance — focus, memory, and studying
• Complete Lion's Mane Benefits Guide — full evidence overview across all studied areas

Frequently Asked Questions

Can lion's mane replace painkillers?

No. Lion's mane has no human research suggests benefits for pain relief and should not be used as a substitute for prescribed or over-the-counter pain medication. The animal studies showing pain modulation (PMID: 29199560, 32508945) are mechanistically interesting but have not been replicated in humans. Always continue prescribed pain management and consult your healthcare provider before adding any supplement.

Is lion's mane good for nerve pain?

Pre-clinical studies show lion's mane may support nerve regeneration (PMID: 23510212, PMID: 30570422) and reduce neuropathic pain behaviour in mice (PMID: 32508945). These findings are mechanistically interesting but have not been tested in human neuropathic pain conditions. Discuss with your neurologist or pain specialist before adding any supplement to your regimen.

Does lion's mane reduce inflammation?

In laboratory and animal models, yes. Erinacine C suppressed NF-κB signalling and reduced pro-inflammatory cytokines including IL-6 and TNF-α (PMID: 31547327). The 2020 neuropathic pain study also showed reduced neuroinflammation markers in mice (PMID: 32508945). However, whether oral lion's mane supplementation produces clinically meaningful anti-inflammatory effects in humans is unknown, and it should not be relied upon for managing inflammatory conditions.

How long would lion's mane take to affect pain?

Unknown — there are no human pain studies from which to estimate onset of effect. The nerve regeneration mechanism would logically require weeks to months of consistent supplementation. Human cognitive studies typically see neurological effects beginning at 4–8 weeks. The purinoceptor modulation shown in animal studies appeared more rapidly, but human dosing and timelines have not been established. Do not delay appropriate medical care while waiting to see if a supplement has any effect.

What compounds in lion's mane are relevant to pain research?

The pain-relevant compounds identified in pre-clinical research include erinacine-S and erinacine-C (both found predominantly in the mycelium), as well as hericenones (in the fruiting body) which stimulate NGF synthesis. The purinoceptor modulation and neuropathic pain studies used mycelium extracts; the peripheral nerve regeneration studies used fruiting body. Different products may therefore have different relevance to different proposed mechanisms.

---

This article is for informational and educational purposes only and does not constitute medical advice. Lion's mane mushroom is a food supplement, not a medicine, and is not intended to diagnose, treat, cure, or prevent any disease or health condition. If you are experiencing pain, please consult a qualified healthcare professional. Do not alter or discontinue prescribed pain medication based on this or any other supplement information. Individual results may vary.

---

Continue Your Research

• Lion's Mane Benefits: What 571 Studies Actually Show
• Lion's Mane for Gut Health: The Prebiotic Bridge Your Microbiome Has Been Waiting For
• Lion's Mane and the Immune System: What the Evidence Shows
• Lion's Mane for Athletes: Performance, Recovery, and Honest Expectations
• Lion's Mane for Energy: Not a Stimulant, Something Different
• Lion's Mane Dosage Guide: Clinical Trial Doses, Extract Conversions & Timing
• Lion's Mane Side Effects: Safety Profile Review
• Lion's Mane for ADHD and Focus: What the Research Actually Shows

← Back to Lion's Mane Research Hub